Peer-reviewed Articles
Viruses 2019, 11(2), 134; https://doi.org/10.3390/v11020134
Twelfth International Foamy Virus Conference—Meeting Report
Herchenröder O, Löchelt M, Buseyne F, Gessain A, Soares MA, Khan AS, Lindemann D.
Cancer Lett. 2018 Nov 13. pii: S0304-3835(18)30673-6. doi: 10.1016/j.canlet.2018.11.009.
DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.
Fürst K, Steder M, Logotheti S, Angerilli A, Spitschak A, Marquardt S, Schumacher T, Engelmann D, Herchenröder O, Rupp RAW, Pützer BM.
Semin Cancer Biol. 2018 Jun 29. pii: S1044-579X(18)30018-X. doi: 10.1016/j.
Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S, Solanki M, Spitschak A, Vera J, Pützer BM.
Biochim Biophys Acta. 2018; 1864(6 Pt B):2315-2328.
A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy.
Dreyer FS, Cantone M, Eberhardt M, Jaitly T, Walter L, Wittmann J, Gupta SK, Khan FM, Wolkenhauer O, Pützer BM, Jäck HM, Heinzerling L, Vera J.
Eur J Microbiol Immunol (Bp) doi.org/10.1556/1886.2018.00007
Diagnostics as Prevention — A Rapid Testing-Based Strategy of Sex Workers against Sexual HIV Exposure
Hahn A, Hinz R, Meyer T, Loderstädt U, Herchenröder O, Meyer CG, Schwarz NG, Frickmann H.
Epidemiol Infect. 2018 Apr 15:1-11.
HIV prevention strategies and risk of infection: a model-based analysis.
Hahn A, Hinz R, Meyer T, Loderstädt U, Herchenröder O, Meyer CG, Schwarz NG, Frickmann H.
Theranostics 2018; 8(4):1106-1120.
MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.
Lai X, Gupta SK, Schmitz U, Marquardt S, Knoll S, Spitschak A, Wolkenhauer O, Pützer BM, Vera J.
Acta Trop. 2018; 179:25–35
Pharmaceutical interactions between antiretroviral and antimalarial drugs used in chemoprophylaxis.
Zautner AE, Herchenröder O, El Moussi A, Schwarz NG, Wiemer DF, Uwe Groß U, Frickmann H.
Nat Commun. 2017 Aug 4;8(1):198.
Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures.
Khan FM, Marquardt S, Gupta SK, Knoll S, Schmitz U, Spitschak A, Engelmann D, Vera J, Wolkenhauer O, Pützer BM.
Adv Drug Deliv Rev. 2017 Jul 20. pii: S0169-409X(17)30120-5. doi: 10.1016/j.addr.2017.07.013.
Advances in cancer stem cell targeting: How to strike the evil at its root.
Pützer BM, Solanki M, Herchenröder O.
European Urology Focus; doi: 10.1016/j.euf.2017.02.009.
E2F1 Signalling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers.
Fenner F, Goody D, Protzel C, Erbersdobler A, Richter C, Hartz JM, Naumann CM, Kalthoff H, Herchenröder O, Hakenberg OW, Pützer BM.
Biochem Biophys Res Commun. 2017 Sep 9;491(1):40-46.
Non-canonical pathway induced by Wnt3a regulates β-catenin via Pyk2 in differentiating human neural progenitor cells.
Narendra Talabattula VA, Morgan P, Frech MJ, Uhrmacher AM, Herchenröder O, Pützer BM, Rolfs A, Luo J.
Mol Cancer. 2017 Jan 26;16(1):24.
MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM
Cell Stem Cell. 2016 Jun 2;18(6):797-808.
Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis
Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay H-C, Yang D, Reetz J, Brandes S, Dai Z, Pützer BM, Araúzo-Bravo MJ, Steinemann D, Luedde T, Schwabe RF, Manns MP, Schöler HR, Schambach A, Cantz T, Ott M, Sharma AD
J Urol. 2016 Aug;196(2):570-8.
Integrated loss of miR-1/-101/-204 discriminates metastatic from non-metastatic penile carcinomas and can predict patient outcome.
Hartz JM, Engelmann D, Fürst K, Marquardt S, Spitschak A, Goody D, Protzel C, Hakenberg OW, Pützer BM.
Cancer Res. 2016 Jan 15;76(2):197-205.
p73 and IGF1R regulate emergence of aggressive cancer stem-like features via miR-885-5p control.
Meier C, Hardtstock P, Joost S, Alla V, Pützer BM.
J Neurooncol. 2016 Feb;126(3):585-92.
Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
Henker C, Kriesen T, Fürst K, Goody D, Glass Ä, Pützer BM, Piek J.
Nucleic Acids Res. 2016 Jan 8;44(1):117-33.
Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures.
Wang Y, Alla V, Goody D, Gupta SK, Spitschak A, Wolkenhauer O, Pützer BM, Engelmann D.
Mol Carcinog. 2016 Aug;55(8):1229-42.
Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of mir-200 family members, mir-205 and their common targets.
Skourti E, Logotheti S, Kontos CK, Pavlopoulou A, Dimoragka PT, Trougakos IP, Gorgoulis V, Scorilas A, Michalopoulos I, Zoumpourlis V.
Transl Res. 2016 Jul;173:58-73.e2.
N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in cancer cells with impaired glucocorticoid receptor.
Logotheti S, Khoury N, Vlahopoulos SA, Skourti E, Papaevangeliou D, Liloglou T, Gorgoulis V, Budunova I, Kyriakopoulos AM, Zoumpourlis V.
J Gen Virol. 2016 Jan;97(1):160-8.
Adenovirus hexon modifications influence in vitro properties of pseudotyped human adenovirus type 5 vectors.
Solanki M, Zhang W, Jing L, Ehrhardt A.
BMC Cancer. 2016 Oct 10;16(1):782.
ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells.
Nekulova M, Holcakova J, Gu X, Hrabal V, Galtsidis S, Orzol P, Liu Y, Logotheti S, Zoumpourlis V, Nylander K, Coates PJ, Vojtesek B.
Cancer Lett. 2016 Dec 3;388:96-106.
Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness.
Galtsidis S, Logotheti S, Pavlopoulou A, Zampetidis CP, Papachristopoulou G, Scorilas A, Vojtesek B, Gorgoulis V, Zoumpourlis V.
Mol Ther Nucleic Acids. 2016 Jul 19;5(7):e337.
A High-Capacity Adenoviral Hybrid Vector System Utilizing the Hyperactive Sleeping Beauty Transposase SB100X for Enhanced Integration.
Boehme P, Zhang W, Solanki M, Ehrke-Schulz E, Ehrhardt A.
Int J Cancer. 2016 Apr 1;138(7):1792-801.
Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R, Schmitt A, Spitschak A, Greiner J, Wang L, Hilgendorf I, Hirt C, Ho AD, Freund M, Schmitt M.
J Vis Exp. 2016 Jan 28;(107):e52894.
Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5.
Ehrke-Schulz E, Zhang W, Schiwon M, Bergmann T, Solanki M, Liu J, Boehme P, Leitner T, Ehrhardt A.
Nature. 2015 Aug 6;524(7563):47-53.
Comprehensive genomic profiles of small cell lung cancer.
George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK
Brain Struct Funct (2016) 221:2049–2059
Novel subventricular zone early progenitor cell-specific adenovirus for in vivo therapy of central nervous system disorders reinforces brain stem cell heterogeneity.
Reetz J, Hildebrandt S, Schmidt A, Meier C, Herchenröder O, Gläser A, Witt M, Pützer BM, Wree A.
Oncogene. 2015 Aug 13;34(33):4287-99.
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.
Engelmann D, Meier C, Alla V, Pützer BM.
EMBO Rep. 2014 Dec;15(12):1315-29.
E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation.
Knoll S, Fürst K, Kowtharapu B, Schmitz U, Marquardt S, Wolkenhauer O, Martin H, Pützer BM.
Sci Signal. 2014 Sep 30;7(345):re9.
Emerging from the shade of p53 mutants: N-terminally truncated variants of the p53 family in EMT signaling and cancer progression.
Engelmann D, Pützer BM.
Retrovirology. 2014 Sep 25;11(1):85.
Obituary: Axel Rethwilm (1959-2014).
Berkhout B, Bodem J, Erlwein O, Herchenröder O, Khan AS, Lever AM, Lindemann D, Linial ML, Löchelt M, McClure MO, Scheller C, Weiss RA.
Oncotarget. 2014 Aug 15;5(15):5893-907.
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
Schipper H, Alla V, Meier C, Nettelbeck DM, Herchenröder O, Pützer BM.
J Pathol. 2014 Nov;234(3):351-64.
Association of RHAMM with E2F1 promotes tumor cell extravasation by transcriptional upregulation of fibronectin.
Meier C, Spitschak A, Abshagen K, Gupta S, Mor JM, Wolkenhauer O, Haier J, Vollmar B, Alla V, Pützer BM.
Exp Cell Res. 2014 Nov 1;328(2):429-43.
Adenoviral overexpression of Lhx2 attenuates cell viability but does not preserve the stem cell like phenotype of hepatic stellate cells.
Genz B, Thomas M, Pützer BM, Siatkowski M, Fuellen G, Vollmar B, Abshagen K.
Viruses. 2014 Apr 2;6(4):1540-63.
Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.
Reetz J, Herchenröder O, Pützer BM.
Cancer Cell, Volume 24, Issue 4, 512-527, 14 October 2013
DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling
Steder M, Alla V, Meier C, Spitschak A, Pahnke J, Fürst K, Kowtharapu BS, Engelmann D, Petigk J, Egberts F, Schäd-Trcka SG, Gross G, Nettelbeck DM, Niemetz A, Pützer BM.
J Mol Cell Biol. 2013 Dec;5(6):391-403.
E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.
Engelmann D, Mayoli-Nüssle D, Mayrhofer C, Fürst K, Alla V, Stoll A, Spitschak A, Abshagen K, Vollmar B, Ran S, Pützer BM.
Virol J. 2013 Aug 28;10(1):269.
Chikungunya virus capsid protein contains nuclear import and export signals.
Thomas S, Rai J, John L, Schaefer S, Pützer BM, Herchenröder O.
Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):289-98.
Hybrid modeling of the crosstalk between signaling and transcriptional networks using ordinary differential equations and multi-valued logic.
Khan FM, Schmitz U, Nikolov S, Engelmann D, Pützer BM, Wolkenhauer O, Vera J.
Cancer Res. 2013 Jun 15;73(12):3511-24.
Kinetic Modeling-Based Detection of Genetic Signatures that Provide Chemoresistance via the E2F1-p73/DNp73-miR-205 Network.
Vera J, Schmitz U, Lai X, Engelmann D, Khan FM, Wolkenhauer O, Pützer BM.
PLoS ONE 8(6): e67091. doi:10.1371/journal.pone.0067091
Development of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In Vivo.
Reetz J, Genz B, Meier C, Kowtharapu BS, Timm F, Vollmar B, Herchenröder O, Abshagen K, Pützer BM.
Adv Exp Med Biol. 2013;774:135-47. doi: 10.1007/978-94-007-5590-1_8.
The E2F1-miRNA Cancer Progression Network.
Knoll S, Emmrich S, Pützer BM.
Trends Mol Med. 2013 Feb;19(2):89-98. doi: 10.1016/j.molmed.2012.10.009. Epub 2012 Dec 5.
E2F1 apoptosis counterattacked: evil strikes back.
Pützer BM, Engelmann D.
Cell Cycle. 2012 Aug 15;11(16):3067-78. doi: 10.4161/cc.21476. Epub 2012 Aug 8.
E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.
Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM.
Clin Dev Immunol. 2012;2012:146463. doi: 10.1155/2012/146463. Epub 2012 Jun 6.
Immune responses to RHAMM in patients with acute myeloid leukemia after chemotherapy and allogeneic stem cell transplantation.
Casalegno-Garduño R, Meier C, Schmitt A, Spitschak A, Hilgendorf I, Rohde S, Hirt C, Freund M, Pützer BM, Schmitt M.
J Cell Mol Med. 2012 Mar 27. doi: 10.1111/j.1582-4934.2012.01573.x. [Epub ahead of print].
Senescence determines the fate of activated rat pancreatic stellate cells.
Fitzner B, Müller S, Walther M, Fischer M, Engelmann R, Müller-Hilke B, Pützer BM, Kreutzer M, Nizze H, Jaster R.
Biotechnol Bioeng. 2012 Mar 22. doi: 10.1002/bit.24505. [Epub ahead of print].
Adenoviral transduction supports matrix expression of alginate cultured articular chondrocytes.
Pohle D, Kasch R, Herlyn P, Bader R, Mittlmeier T, Pützer BM, Müller-Hilke B.
Cancer Res. 2012 Feb 1;72(3):571-5. Review.
The dark side of E2F1: in transit beyond apoptosis.
Engelmann D, Pützer BM.
Cell Cycle. 2011 Oct 31;10(20).
Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: A role for HBV-induced HCC.
Knoll S, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schäfer S, Pützer BM.
PLoS One. 2011;6(9):e25378. Epub 2011 Sep 23.
Hepatitis E Virus ORF2 Protein Activates the Pro-Apoptotic Gene CHOP and Anti-Apoptotic Heat Shock Proteins.
John L, Thomas S, Herchenröder O, Pützer BM, Schaefer S.
Clin Endocrinol (Oxf). 2011 Jun 28.
Germline RET Sequence Variation I852M and Occult Medullary Thyroid Cancer: Harmless Polymorphism or Causative Mutation?
Machens A, Spitschak A, Lorenz K, Pützer BM, Dralle H.
Gene Ther. 2011 Apr;18(4):418-23.
Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models. Gene Ther. 2011 Apr;18(4):418-23.
Schmidt A, Eipel C, Fürst K, Sommer N, Pahnke J, Pützer BM.
Virol J. 2010 Nov 18;7(1):327.
Functional dissection of the alphavirus capsid protease: sequence requirements for activity.
Thomas S, Rai J, John L, Gunther S, Drosten C, Pützer BM, Schäfer S.
Drug Res Updates. 2010 Aug-Oct;13(4-5):119-31.
Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.
Engelmann D, Pützer BM.
Expert Rev Anticancer Ther. 2010 Nov;10(11):1707-1720.
Predicting and preventing melanoma invasiveness: advances in clarifying E2F1 function.
Pützer BM, Steder M, Alla V.
Cell Death Differ. 2010 Dec 3. Epub ahead of print.
GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
John K, Alla V, Meier C, Pützer BM.
Brain Struct Funct. 2010 Jul 22.
Targeting of neural stem cells in the hippocampus of adult rats by custom-made Ad vectors.
Hildebrandt S, Schmidt A, Stoll A, Schmitt O, Köhling R, Wree A, Haas SJP, Pützer BM.
Cell Cycle. 2010; 9(13):2555-2567.
Checks and balances: E2F – microRNA crosstalk in cancer control.
Emmrich S, Pützer BM.
J Nat Cancer Inst. 2010;102(2):127-133.
E2F1 in melanoma progression and metastasis.
Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D, Pützer BM.
Cell Mol Life Sci. 2010;67:931-948
Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.
Engelmann D, Knoll S, Ewerth D, Steder M, Stoll A, Pützer BM.
Molecular Cancer. 2009; 8:61 doi:10.1186/1476-4598-8-61.
Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo.
Emmrich S, Wang W, John K, Li W, Pützer BM.
Endocrine-Related Cancer. 2009; 16:211-224.
Transcriptome analysis in mouse tumors induced by RET-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D, Koczan D, Ricken P, Rimpler U, Pahnke J, Li Z, Pützer BM.
J Biol Chem. 2008; 283(49):34305-34314.
Transcriptional repression of the prosurvival ER chaperone GRP78/BIP by E2F1.
Racek T, Buhlmann S, Rüst F, Knoll S, Alla V, Pützer BM.
J Gene Med. 2008; 10(8):897-909.
Enhanced thoracic gene delivery by magnetic nanobead-mediated vector.
Li W, Ma N, Ong L-L, Kaminski A, Skrabal C, Ugurlucan M, Lorenz P, Gatzen HH, Lützow K, Lendlein A, Pützer BM, Li R-K, Steinhoff G.
Eur J Endocrinol. 2008 Jun;158(6):811-816. Epub 2008 Mar 5.
Characterization of the RET protooncogene transmembrane domain mutation S649L associated with nonaggressive medullary thyroid carcinoma.
Colombo-Benkmann M, Li Z, Riemann B, Hengst K, Herbst H, Kreuser R, Gross U, Rondot S, Raue F, Senninger N, Pützer BM, Frank-Raue K.
J Mol Biol. 2008; 378(1):20-30. Epub 2008 Feb 20.
Molecular mechanism of p73-mediated regulation of Hepatitis B virus core promoter/enhancer II: Implications for hepatocarcinogenesis.
Buhlmann S, Racek T, Schwarz A, Schaefer S, Pützer BM.
Biochim Biophys Acta (Reviews-on-cancer). 2008; 1785(2):207-216.
DNp73 a matter of cancer: Mechanisms and clinical implications.
Buhlmann S, Pützer BM.
J Cell Mol Med. 2008; 12(6A):2427-2438.
Spliceosomal protein E regulates neoplastic cell growth by modulating expression of cyclin E/CDK2 and G2/M checkpoint proteins.
Li Z, Pützer BM.
Carcinogenesis 2008; 29(1):211-218. Epub 2007 Nov 4.
Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor deltaNp73.
Tannapfel A, John K, Miše N, Schmidt A, Buhlmann S, Ibrahim SM, Pützer BM.
Stem Cells 2007; 25(11):2910-2918.
Selective targeting of adenoviral vectors to neural precursor cells in the hippocampus of adult mice: New prospects for in situ gene therapy.
Schmidt A, Haas SJ-P, Hildebrandt S, Scheibe J, Eckhoff B, Kempermann G, Wree A, Pützer BM.
J Cell Mol Med. 2007; 11(2): 239-251.
E2F1 death pathways as targets for cancer therapy.
Pützer BM.
Discov Med. 2006; 6(33):123-127.
Targeting E2F1 death signaling: Opposing role in cancer control and neurodegeneration.
Pützer BM.
Clin Pract Oncol. 2006; 3:564-574.
Cancer targeting: impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M, Pützer BM.
Proteomics. 2006; 6:5735-5745.
Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death.
Li Z, Kreutzer M, Mikkat S, Miše N, Glocker, MO, Pützer, BM.
Oncogene. 2006; 25:6637-6647.
Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.
Miše N, Drosten M, Racek T, Tannapfel A, Pützer BM.
Trends Mol Med. 2006; 12:177-185.
E2F1-related apoptosis: turning killers into therapeutics.
Stanelle J, Pützer BM.
Apoptosis. 2006; 11:235-244.
Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas.
Tuve S, Racek T, Niemetz A, Schultz J, Soengas MS, Pützer BM
J Biol Chem. 2005; 280:40402-40405.
C-terminal p73 isoforms repress transcriptional activity of the human telomerase reverse transcriptase (hTERT) promoter.
Racek T, Miše N, Li Z, Stoll A, Putzer BM
Hum Gene Ther. 2005; 16:1267-1275.
Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.
Böckmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BAJ, Pützer BM.
Curr Eye Res. 2005; 30:1051-1059.
Gene transfer to trabecular meshwork endothelium via direct injection into Schlemm’s canal and in vivo toxicity study.
Hudde T, Apitz J, Johnson K, Bordes-Alonso R, Heise K, Johnson KTM, Steuhl K-P, Pützer BM.
Virus Res. 2005; 114:45-53.
Analysis of adenovirus gene transfer into adult neural stem cells.
Schmidt A, Böckmann M, Stoll A, Racek T, Pützer BM.
Nucleic Acids Res. 2005; 33:2813-2821.
Selection of novel mediators of E2F1-induced apoptosis through retroviral expression of an antisense cDNA library.
Li Z, Stanelle J, Leurs C, Hanenberg H, Pützer BM.
Cell Death Differ. 2005; 12:347-357.
A novel mitochondrial Protein DIP mediates E2F1-induced apoptosis independently of p53.
Stanelle J, Tu-Rapp H, Pützer BM.
Brit J Ophthalmol. 2005; 89: 508-512.
Adenoviral p53 gene transfer inhibits human Tenon´s capsule fibroblast proliferation.
Johnson KTM, Rödicker F, Heise K, Heinz C, Steuhl KP, Pützer BM, Hudde T.
J Gene Med. 2005; 7:179-188.
Discovery of targeted peptides for selective therapy of medullary thyroid carcinoma.
Böckmann M, Drosten M, Pützer BM.
Trends Mol Med. 2004; 10:351-357.
The RET proto-oncogene: A valuable target for molecular cancer therapy.
Pützer BM, Drosten M.
J Nat Cancer Inst. 2004; 96:1231-1239
Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M, Hilken G, Böckmann M, Rödicker F, Misê N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.
J Virol. 2004; 78:10111-10121.
Helper-dependent adenoviral vector-mediated delivery of woodchuck specific genes for interferon alpha (IFNa) and gamma (IFNg): IFNa reduces woodchuck hepatitis virus replication more efficiently than IFN does in chronic infection in vivo.
Fiedler M, Rödicker F, Salucci V, Lu M, Aurisicchio L, Dahmen U, Jun L, Dirsch O, Pützer BM, Palombo F, Roggendorf M.
Int J Cancer. 2004; 108: 162-166
Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression.
Tuve S, Wagner S, Schittek B, Pützer BM.
Clin Cancer Res. 2004; 10:626-633.
Quantitative TP73 transcript analysis in hepatocellular carcinomas.
Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM.
J Hepatol. 2004; 40:354-356.
Diagnosis of biliary duct cysts in transgenic mice expressing the hepatitis B virus X-protein.
Dirsch O, Rödicker F, Herborn CU, Hilken G, Pützer BM.
Cell Death Differ. 2003; 10:612-614.
Increased DN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promotor derived DN'-p73 transcript.
Pützer BM, Tuve S, Tannapfel A, Stiewe T.
J Biol Chem. 2003; 278:14230-14236.
Inactivation of the RB tumor suppressor gene by oncogenic isoforms of the p53 family member p73.
Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM.
Cancer Res. 2003; 63:2737-2741.
p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement.
Rödicker F, Pützer BM.
J Mol Med 2003; 81:411-419.
Gene therapeutic approaches for medullary thyroid carcinoma treatment.
Drosten M, Pützer BM.
Hum Gene Ther. 2003; 14:971-982.
Antitumor capacity of dominant-negative RET proto oncogene mutant in a medullary thyroid carcinoma model.
Drosten M, Stiewe T, Pützer BM.
Cardiovasc Res. 2003; 59:512-519.
Mechanism of E2F1-induced apoptosis in primary vascular smooth muscle cells.
Stanelle J, Stiewe T, Rödicker F, Köhler K, Theseling CC, Pützer BM.
Mol Ther. 2002; 5:405-412.
Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a non-immunogenic tumor model.
Pützer BM, Rödicker F, Hitt MM, Stiewe T, Esche H.
Cell Death Differ. 2002; 9:237-246.
Role of p73 in malignancy: tumor suppressor or oncogene?
Stiewe T, Pützer BM.
J Biol Chem. 2002; 277:14177-14185.
Transactivation-deficient DTA-p73 inhibits p53 by direct competition for DNA-binding: implications for tumorigenesis.
Stiewe T, Theseling C, Pützer BM.
Nucleic Acids Res. 2002; 30:1859-1867.
Gene expression changes in response to E2F1 activation
Stanelle J, Stiewe T, Theseling CC, Peter M, Pützer BM.
Cancer Res. 2002; 62:3598-3602
Transactivation-deficient DN-p73 acts as an oncogene.
Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM.
Surgery 2002; 132:991-997
A new therapeutic approach in MTC treatment: Inhibition of oncogenic RET signalling by Ad vector-mediated expression of a dominant-negative RET mutant.
Drosten M, Frilling A, Stiewe T, Pützer BM.
Mol Cell Neurosi. 2001; 17:68-79.
Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor.
Rega S, Stiewe T, Chang D-I, Pollmeier B, Esche H, Bardenheuer W, Marquitan G, Pützer BM.
J Natl Cancer Inst. 2001; 93:472-479.
Large Nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin-12/B7.1 genes.
Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Dahmen U, Tennant B, Scherer C, Graham FL, Roggendorf M.
Cancer Res. 2001; 61:7052-7055.
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.
Rödicker F, Stiewe T, Zimmermann S, Pützer BM.
Nat Genet. 2000; 26:464-469.
Role of the p53-homolog p73 in E2F1-induced apoptosis.
Stiewe T, Pützer BM.
Gene Ther. 2000; 7:1317-1325.
Improved safety through tamoxifen-regulated induction of cytotoxic genes delivered by Ad vectors for cancer gene therapy.
Pützer BM, Stiewe T, Crespo F, Esche H.
Cell Death Differ. 2000; 7:177-188.
E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products.
Pützer BM, Stiewe T, Parssanedjad K, Rega S, Esche H.
Tumor Diag Ther. 2000; 21:1-7.
The Role of Tumor Suppressor Gene Therapy for Anticancer Treatment.
Pützer BM.
Cancer Res. 2000; 60:3957-3964.
E1A overcomes the apoptosis block in BCR/ABL-positive leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents
Stiewe T, Parssanedjad K, Esche H, Opalka B, Pützer BM.
Gene Expression. 1999; 8:1-18.
A multi-protein complex consisting of the cellular coactivator p300, AP-1/ATF as well as NF-kB is responsible for the activation of the mouse major histocompatibility class I (H-2Kb) enhancer A.
Brockmann, Pützer BM, Lipinski KL, Schmücker U, Esche H
Proc Natl Acad Sci USA. 1997; 94:10889-10894.
Combination therapy with Interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer.
Pützer BM, Bramson J, Addison CL, Hitt M, Siegel P, Muller WJ, Graham FL.
Proc Natl Acad Sci USA. 1997; 94:10889-10894.
Interleukin-12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression.
Pützer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL.
J Virol. 1997; 71:9538-9548.
E1A 12S and 13S of the transformation-defective adenovirus type 12 strain CS-1 inactivate proteins of the RB family, permitting transactivation of the E2F-dependent promoter.
Pützer BM, Rumpf H, Rega S, Brockmann D, Esche H.
J Gen Virol. 1997; 78:879-891
A cis-acting element 7 bp upstream of the ESF-1-binding motif is involved in E1A 13S autoregulation of the adenovirus 12 TS2 promoter.
Pützer BM, Gnauck J, Kirch HC, Brockmann D, Esche H.
Eur J Biochem. 1997; 246:736-744
Formation of the early-region-2 transcription-factor-1-retinoblastoma-protein (E2F-1-RB) transrepressor and release of the retinoblastoma protein from nuclear complexes containing cyclin A is induced by interferon in U937V cells but not in interferon--resistant U937VR cells.
Kirch HC, Pützer BM, Brockmann D, Esche H, Kloke O.
Cell Mol Biol Res. 1993; 39:705-716
Regulation of Ad12 E1A transcription: E2F and ATF motifs in the E1A promoter bind nuclear protein complexes including E2F, DP-1 cyclin A, and/ or RB and mediate transcriptional (auto)activation.
Kirch HC, Pützer BM, Schwabe G, Krüger H, Gnauck J, Schulte Holthausen H.
